Announcement on 2023 Annual Preliminary Earnings Estimate
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on 2023 Annual Preliminary Earnings Estimate
Filed with SSE ·
Announcement on 2023 Annual Preliminary Earnings Estimate
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
6ix hasn’t read this filing yet.
Earlier from BeOne Medicines
- Announcement on Signing Consulting Agreement and Related Transaction
- Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for Circulation
- Announcement on Adjusting Investment Amount of Raised Funds Invested in Investment Subproject Financed by Raised Funds
- Announcement on Convening 2023 3rd Quarter Performance Meeting
- Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic Leukemia
Later from BeOne Medicines
- Announcement on Progress in Joint Investment with Related Party and Related Transaction
- Announcement on Appointing Member of Advisory Committee on Commercial and Medical Affairs of Board of Directors
- Announcement on Equity Registration Date of 2024 Annual General Meeting
- Announcement on Convening 2023 Annual Performance Meeting
- Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines